Camurus (NASDAQ:CAMX) announced Monday that Eli Lilly (NYSE:LLY) has formally exercised its option to integrate amylin receptor agonists into the companies' existing cardiometabolic collaboration and license agreement.
Cosmos Health (NASDAQ:COSM) generated record revenue in the first quarter of 2026, driven by sustained distribution gains and market expansions, even as a shifting business mix and operational investments weighed on bottom-line profitability.
CorVel (NASDAQ:CRDL) reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, delivering top-line expansion and a double-digit increase in earnings per share as investments in artificial intelligence and automation optimized clinical workflows.
Lifeway Foods (NASDAQ:LWAY) reported a surge in first-quarter revenue that far outpaced analyst estimates, extending a multi-year growth streak fueled by the mainstreaming of gut-health products.
DarioHealth (NASDAQ:DRIO) posted first-quarter revenue of $5.6 million, a 6.7% increase from the fourth quarter of 2025.
Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported its financial results for the first quarter ended March 31, 2026.
BrainsWay (NASDAQ:BWAY) delivered a powerful first-quarter 2026 performance, marked by a 35% year-over-year revenue increase to $15.5 million.
Dyne Therapeutics (NASDAQ:DYN) ended the first quarter of 2026 with $972.2 million in cash, cash equivalents, and marketable securities.
Warby Parker (NYSE:WRBY) reported first-quarter results for 2026 that exceeded internal guidance across all key financial metrics, signaling resilient demand for its affordable luxury eyewear and integrated vision services.
IDEXX Laboratories (NASDAQ:IDXX) increased its financial projections for 2026 following a first quarter marked by robust demand for pet healthcare services and significant margin expansion within its core diagnostic segments.
BrightSpring Health Services (NASDAQ:BTSG) reported a landmark first quarter for 2026, delivering substantial growth across all key financial metrics.
Kodiak Sciences (NASDAQ:KOD) is set to present a series of clinical and preclinical advances at the American Uveitis Society (AUS) and the Association for Research in Vision and Ophthalmology (ARVO) annual meetings between May 2 and May 7, 2026.
